Φορτώνει......
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
BACKGROUND: Prostate cancer that progresses after enzalutamide treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen therapy [BAT]) in this setting might induce tumour responses. We ai...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Lancet Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5875180/ https://ncbi.nlm.nih.gov/pubmed/29248236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30906-3 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|